ABSTRACT: Introduction: We developed an evaluatoradministered functional facioscapulohumeral muscular dystrophy composite outcome measure (FSHD-COM) comprising patientidentified areas of functional burden for future clinical trials. Methods: We performed a prospective observational study of 41 patients with FSHD at 2 sites. The FSHD-COM includes functional assessment of the legs, shoulders and arms, trunk, hands, and balance/mobility. We determined the test-retest reliability and convergent validity compared to established FSHD disease metrics. Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent muscular dystrophies, with a world-wide prevalence range of 2-7:100,000).
functional composite outcome measure suitable for future FSHD clinical trials that shows excellent test-retest reliability and crosssectional associations to disease measures. Future directions include determining multisite reliability, sensitivity to change, and the minimal clinically important change in the FSHD-COM.
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Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent muscular dystrophies, with a world-wide prevalence range of 2-7:100,000). 1 It is often thought of as a slowly progressive condition; however, it can result in significant lifetime morbidity, with approximately 20% of individuals requiring a wheelchair or becoming disabled due to FSHD. 2, 3 Advances in the genetic understanding of FSHD have identified the aberrant expression of the gene DUX4 as a potential target for therapy, which has shifted focus in the research community toward clinical trial planning. 4, 5 A prior natural history study developed procedures and tested the reliability and validity of measures of strength and separate individual functional outcome measures (e.g., timed 30-foot go test, time to climb 4 stars), which have been used in clinical trials. [6] [7] [8] Despite this, no individual functional outcome assessment has demonstrated sensitivity to disease progression in FSHD, and no individual functional measure captures the full range of patient-identified disability. 9 A performance-based functional composite outcome measure that combines multiple functional domains and individual evaluator-administered items into 1 measure and captures key components of patientidentified disease burden could help hasten drug development by documenting functionally relevant changes in FSHD with therapy, putting small changes in composite strength or biomarkers in a clinically meaningful context, and supporting drug registration applications.
Here we describe a new evaluator-administered functional FSHD composite outcome measure (FSHD-COM) and determine test-retest reliability and convergent validity of this instrument Additional supporting information may be found online in the Supporting Information section at the end of the article.
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MATERIALS AND METHODS
We performed a prospective cross-sectional study across 2 sites (University of Rochester Medical Center [URMC] and The Ohio State University Wexner Medical Center) between February 2013 and November 2016. The protocol was approved by the human subject research committees at both institutions, and all participating individuals provided written and informed consent. Participants between 18 and 75 years of age, genetically confirmed, clinically affected, and able to walk at least 30 feet without assistance from another person (assistive devices and bracing allowed) were eligible to participate in this study. 10, 11 Participants with other medical conditions that could interfere with safe performance of study procedures could have been excluded at the discretion of the investigator, but no participant was excluded for this reason. Consecutive willing participants were recruited from the clinical research center, the URMC neuromuscular research database, or the National Registry for Myotonic Dystrophy & Facioscapulohumeral Dystrophy of Patients and Family Members (National Registry). The inclusion criteria were designed to match the most likely criteria used for clinical trials, which would be genetically defined and clinically affected individuals with FSHD who are still ambulatory.
Outcomes and Measures. Participants completed a half day baseline visit in the clinical research center, and local participants or those able to return for a second visit returned within 3 weeks for test-retest reliability testing (University of Rochester only). In addition to basic demographics and FSHD medical history, disease severity was assessed by using a clinical severity scale that documents muscle involvement in the face, shoulders, arms, abdomen, and legs (0 5 unaffected, 15 5 severely affected/nonambulatory). 12 Time since onset of symptoms and time since diagnosis of FSHD were recorded separately as measures of disease duration.
The FSHD-COM is an 18-item evaluator-administered instrument. The items chosen for the FSHD-COM represent body areas impacted by the disease and are based on (1) consensus expert opinion about muscle involvement and progression, (2) muscle involvement and functional limitations seen in a prior natural history study, (3) patientreported surveys and registry data, and (4) patterns of muscle involvement seen on MRI studies (Supp. Info. Fig.  1 ). 9, [13] [14] [15] [16] [17] The functional tasks are standardized, evaluator administered, and reported in the literature. The body regions represented are leg function, shoulder and arm function, trunk function, hand function, and balance/ mobility. Each component is scored on a 0-4 scale, with 0 representing unaffected/normal performance, and the divisions are based on healthy population normative values and standard deviation (where available) or the relative degree of ability to perform the functional task (Supp. Info. Methods). The scale has a maximum total of 72 points, with more items chosen for the 2 most frequently patient-cited areas of functional motor concern, leg function and shoulder and arm function. The FSHD-COM takes approximately 35 min to complete, including a 10-min rest prior to the 6-minute walk test (6MWT).
Leg Function. The leg subscale is composed of 6 different continuous measures that are converted to a 0-4 ordinal scale by using divisions as described above, for a maximum total of 24 points. The leg function tasks test a range of different abilities from power to endurance to balance and climbing. The timed sit-to-stand tests proximal lower extremity strength and core strength by having participants stand from a standard-height chair. 18, 19 The 6MWT is a measure of functional exercise capacity that requires both strength and physical endurance. It assesses how far an individual can walk in 6 min and is used widely in studies involving neuromuscular disease. [20] [21] [22] Self-selected gait speed is used as a measure of overall health status in the elderly and was previously used in a study of dynamic motion in FSHD. 23, 24 The 30-foot go test is a measure of speed and strength in which participants are asked to traverse 30 feet as fast as they can safely, including running. The time to ascend 4 stairs is a functional activity that requires proximal leg strength; both the 30-foot go test and the time to ascend 4 stairs are predictors of loss of ambulation for Duchenne muscular dystrophy.
22,25
Shoulder and Arm Function. The shoulder and arm function category tests proximal to mid-arm tasks and the ability to coordinate upper extremity function across a variety of muscle groups. The shoulder/arm subscale includes 7 items for 28 points. The tasks are an adaptation of the activities contained in the Brooke upper extremity scale, in which a weight is added to mimic functional activities such as lifting a gallon of milk and, for elbow function, to mimic lifting groceries. 9, 25, 26 The time to don and doff a coat is a more complex task that incorporates functional use of both proximal and mid-limb muscles. 27 Trunk Function. There are no specific functional tasks designed to measure trunk function in FSHD, so we chose practical tasks which will reflect changes in core truncal muscle groups. This subscale includes 3 items (maximum 12 points). Picking a penny up off the floor tests the ability to bend and straighten but also balance and the ability of lower extremity muscles to compensate for core weakness; this test has been used in the elderly. 27 The ability to sit up from lying supine and the timed supine-to-sitting at edge of bed test reflects core muscle strength and coordination. 28 The ability to get out of a bed was one of the most frequently patient-identified areas of functional loss over 6 years. 2 Hand Function. Hand grip strength has widely been reported as an independent predictor of morbidity and mortality in aging populations, is intrinsically related to performing daily activities, is abnormal in individuals with FSHD, and was the most sensitive strength measure in assessing a response to albuterol in a randomized controlled trial. 6, 7, 29, 30 Hand grip is measured bilaterally and contributes 4 points to the FSHD-COM score.
Balance Function. Balance and mobility are assessed by using the timed up and go (TUG), a standard outcome measure for the elderly that is increasingly being used in neuromuscular disorders. Participants are asked to rise from a chair, walk 3 meters, turn 180 degrees, and return to a seated position in the chair. It assesses strength, mobility, and balance. [31] [32] [33] This task is timed and then scored 0-4. The FSHD-COM is displayed in Table 1 .
Standard manual muscle testing (MMT) was performed on 14 bilateral muscle groups (shoulder abductors and external rotators; elbow flexors and extensors; wrist flexors . Muscles scores were averaged to create whole body or body region subscores (e.g., lower extremity). Quantitative myometry (QMT) was performed with a fixed myometry testing system (QMA, Gainesville, GA) on 8 -bilateral muscle groups (shoulder abductors and external rotators, elbow flexors and extensors, knee flexors and extensors, ankle dorsiflexors, and handgrips). 7 Scores were standardized by using regression equations with normative data to yield the number of standard deviations from predicted normal strength, after accounting for age, sex, and height, and averaged to create composite total body or regional scores. 34 Patient-reported functional burden and the emotional and social impact of FSHD on daily life were determined by using standard, previously validated scales, including the 36-Item Short-Form Health Survey (SF-36), the PROMIS 57, and the Facial Disability Index. [35] [36] [37] MMT, QMT, and the FSHD-COM were performed by physical therapists with experience testing individuals with FSHD. Standardized testing procedures were created and used by both sites. Test-retest reliability was performed by the same evaluating therapist.
Statistical Analysis. Sample characteristics were presented by using means, standard deviations, minimum and maximum values, or frequency and percentage. Reliability was determined by comparing the baseline testing to testing at 3 weeks by using intraclass correlation coefficient (ICC) determined from a linear mixed-effects model. Correlations between the FSHD-COM and other FSHD disease metrics of interest (clinical severity, disease duration, strength testing, or patient-reported disability) were determined by Pearson correlation coefficient. Internal consistency of the FSHD-COM was assessed by using item-total correlations and Cronbach's a. In addition, correlations between scored items of the FSHD-COM were determined by Spearman rank analysis. Floor effect was determined by the frequency of participants scored with the minimal value of a scale; ceiling effect was determined by the frequency of participants scored with the maximal scale value. The slope of the FSHD-COM compared to clinical severity (and 95% confidence interval [95% CI]) was determined from a linear model with the FSHD-COM as the dependent variable and the FSHD clinical severity score, age, and sex as the independent variables. The minimal detectible change beyond which we can be 90% certain (MDC90) a true change occurred was calculated from the intraclass correlation and mean square error. 38, 39 Differences between groups (men or women, genetic mutation, disability or employment status) were determined by 2 sample t tests. P < 0.05 was considered significant, and all testing was two-sided. The Holm method was applied for multiple comparisons. 40 Statistical testing was performed in SPSS 22 (IBM, Armonk, NY) or STATA 11.2 (StataCorp, College Station, TX).
RESULTS
Forty-one individuals with FSHD (FSHD1 5 85%) participated in this study. Participants were mostly (63%) men and middle aged but represented the full range of adult age (22-70 years, Table 2 ). Overall, participants were moderately affected, with an average FSHD clinical severity of 7.1, which roughly equates to face, shoulder, and the beginnings of lower extremity involvement. However, participants demonstrated the full range of ambulatory severity. The individuals in this study were able to complete all tasks and tolerated all testing well. The mean, range, and standard deviation of all of the scored FSHD-COM items are summarized in Table 3 . The reliability of the total score and the subscale components of the FSHD-COM were excellent (ICC 0.90-0.96, Table 4 ). The Cronbach's a for the entire scale was 0.79 and ranged from 0.70 to 0.80 for the subscales, demonstrating good internal consistency. Interitem correlations were overall moderate (Supp. Info. Table 1 ). The test-retest reliability of the continuous subcomponents of the FSHD-COM was good to excellent (ICC 0.69-0.99, Supp. Info. Table 2 ).
The sample mean for the overall FSHD-COM of 25.44 (range, 3-51; SD 14.30) is not quite midscale, which would be consistent with a population who are still ambulatory and moderately affected. By using the standard deviation and the ICC, the MDC90 was determined to be 6.67, or a change of 9.3% on the FSHD-COM total scale. Neither ceiling nor floor effects were seen with the overall FSHD-COM.
Correlations of the FSHD-COM to disease severity, duration, and strength were moderate to strong (Pearson correlation coefficients range j0.63-0.91j, Table 5 ). The associations were equally strong whether looking at upper extremity or lower extremity summary strength scores, which would be expected for a scale with a relatively equal weight for leg, shoulder, and arm function. From the linear model, for each increase of 1 in the FSHD clinical severity score, the FSHD-COM increased by 4.3 (95% CI [3.5, 5.2]) after adjusting for sex and age.
Correlations to patient-reported disease burden were strong for physical components (the SF-36 physical composite and the PROMIS 57 physical score) but not for emotional components (Table 6 ). There was a moderate association between the FSHD-COM and the PROMIS 57 social satisfaction subscore. The FSHD-COM was able to distinguish between participants on the basis of disability and employment status, with participants who are disabled or unemployed being more severely affected (Table 7) .
DISCUSSION
We based our conceptual framework for the FSHD-COM on expert opinion about FSHD progression, natural history studies, MRI studies, and patient surveys and registries. Recent MRI studies have revealed early involvement of muscles not only of the shoulder girdle and arms but also the trunk, pelvic girdle, and thigh. 13, 14, 17 Open-ended interviews revealed that the most commonly quoted functional motor limitations are problems with mobility and ambulation, arm, and shoulder limitations. 15 The most frequently reported functional motor limitations over 6 years in the National Registry were difficulty getting up from lying down in bed and difficulty using arms for activities of daily living.
2 From a practical standpoint, this means that improving gait and mobility and trunk or arm function would be meaningful to patients, and outcomes that reflect these functional domains are important for FSHD clinical trials.
The classic clinical model for FSHD suggests a descending muscular progression affecting first the mimetic muscles of the face, scapular fixators, and humeral muscles; followed by muscles of the abdomen and paraspinal region; and, later, muscles of the lower extremity in a scapuloperoneal pattern. 3, 16 In actuality, there is considerable variability between individuals and side-to-side asymmetry in muscular involvement. 17 To capture the descending progression and side-to-side asymmetry, the FSHD-COM scores the left and right sides separately and contains subcomponents which match major areas of muscular involvement, with the exception of the face. Although severe facial weakness, when present, can be socially limiting, for most people with FSHD, the weakness in the face tends to be relatively static. A prior natural history study could not show changes in the time to drink 6 ounces of water through a straw over follow-up periods as long as 3 years. 7, 9 In development of the FSHD-COM, we tried a variety of measures of facial function, including a timed reading passage and dysdiadokinetic syllable rates, but these did not correlate well to disease severity and showed poor test-retest reliability, so they were not included in the final instrument. In a prior natural history study, functional motor tasks including the time to get up from a chair, timed 30-foot go test, and time to ascend 4 stairs were reliable and showed good crosssectional associations to disease metrics, but individually they were not sensitive to disease progression. 9 By combining functional tasks from multiple body regions, the FSHD-COM may provide a more thorough perspective on the patient's disease state and prove more versatile when following a population of patients that have disease progression involving multiple diverse muscle groups.
The FSHD-COM includes ambulatory items that were chosen to represent different stages in FSHD ambulatory loss, whereby people may still be able to walk after losing the ability to go up or down stairs or get out of chairs without assistance. In the National Registry, the frequency of progression to requiring use of a wheelchair over 6 years was 24%. 2 Participants often remain ambulatory even after requiring a wheelchair for distance; only 10% use a wheelchair for all mobility. From a practical point of view, when designing a functional composite measure, this means that the majority of referred clinical trial participants will likely be ambulatory, and the likelihood of these participants losing ambulation in a 1-2 year study is relatively low. As a participant moves closer to requiring a wheelchair for mobility, they will be unable to perform certain FSHD-COM gait or mobility tasks but not all functional tasks (e.g., they may lose the ability to climb 4 stairs or get up from a chair before losing the ability to perform the 30-foot go test), thus receiving a score of 4 for unable to perform. Although this study assessed only individuals who were ambulatory, individuals who are nonambulatory would have a minimum score of 24, with the remainder of the FSHD-COM reflecting shoulder, arm, and trunk impairment.
Recent MRI studies have challenged some of the clinical preconceptions about the temporal pattern of muscle involvement, revealing early involvement not only of muscles of the shoulder girdle, as previously described, but also paraspinal, semimembranosus, and rectus femoris muscles. 13, 14, 17 The current FSHD-COM is designed to maximize the sensitivity to this early muscle involvement, and the MRI-pattern supports the array of different functional motor tasks designed to tease out different aspects of truncal instability and gait and balance. The strong correlations between the FSHD-COM and disease severity, disease duration, strength, and patient-reported physical impairment support the utility of the scale to measure something meaningful to patients. The minimal clinical meaningful change is an important concept that helps to determine the smallest change in a scale that would be meaningful to patients, usually by using a simple anchor to determine patients who improved (or worsened) a little, then seeing the corresponding average change in the scale. This study was not designed to determine the minimal clinical meaningful change because it was cross-sectional. That said, statistical approaches can be used to determine how large a change in the FSHD-COM would be statistically detectible or would relate to a change in clinical severity; such approaches suggest that a change of approximately 7 points (or a change of about 10% on a 72 point scale) would be outside that expected for chance and that 4 points would equate to an estimated 1 point change on an FSHD clinical severity scale.
Limitations of the current study include the modest-sized sample and recruitment from 2 centers. The small sample and cross-sectional nature of the present study limit the ability to comment on sample size requirements and sensitivity to change. In addition, the small sample prohibited more sophisticated psychometric analyses to assess fully the ability of items to distinguish accurately between functional domains or to determine the relative contribution of individual items to the total score (e.g., Rasch or factor analysis). A larger multicenter study is in progress to validate the items of the scale, determine the reliability across multiple sites with multiple evaluators, and determine the relative responsiveness of the FSHD- COM to disease progression. Such a study may also allow us to examine the contribution of genetic or environmental factors to the variability observed in the present study as well as to determine the minimum clinically important difference.
In conclusion, we present a new FSHD-specific, functional composite outcome measure made up of standard evaluator-administered functional motor tasks. We show the FSHD-COM to be reliable on repeated days of testing and to correlate strongly with a number of other established FSHD disease measures.
